Top Tweets for #CodeBreak300

over 1 year ago

#Sotorasib (+ Panitumumab) now @US_FDA approved for mCRC w/ KRAS G12C after 5FU, Oxali, and Irin based off #CODEBREAK300: - 960mg QDay - PFS 5.6mos (vs 2mos), ORR 26%, OS not significant - Adagrasib (+ Cetux) ✅ based off #KRYSTAL1 #gism #OncTwitter #MedTwitter #crcsm

OncBrothers's tweet photo. #Sotorasib (+ Panitumumab) now @US_FDA approved for mCRC w/ KRAS G12C after 5FU, Oxali, and Irin based off #CODEBREAK300:

- 960mg QDay
- PFS 5.6mos (vs 2mos), ORR 26%, OS not significant
- Adagrasib (+ Cetux) ✅ based off #KRYSTAL1

#gism #OncTwitter #MedTwitter #crcsm https://t.co/fIXV4CDJ5G

FDA Oncology @FDAOncology

over 1 year ago

FDA approves sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer https://t.co/Ile5FhDjjX #OCENewsBurst

53K

20K

Filip Janku

@FilipJankuMD

over 2 years ago

#KRYSTAL1 pooled efficacy data with cetuximab are out, presented by @skopetz. No surprise there and the combo of cetuximab and adagrasib appear to be effective in G12C mutated #CRC #AACR24 #KRAS #G12C. Data summarized in the context of #CodeBreaK300 https://t.co/V2dpB3zfxj

FilipJankuMD's tweet photo. #KRYSTAL1 pooled efficacy data with cetuximab are out, presented by @skopetz. No surprise there and the combo of cetuximab and adagrasib appear to be effective in G12C mutated #CRC #AACR24 #KRAS #G12C. Data summarized in the context of #CodeBreaK300 https://t.co/V2dpB3zfxj https://t.co/iyVm8DNMY8

Oncology Brothers

@OncBrothers

over 2 years ago

#ESMO23 GI Highlights w/ @rachnatshroff - #CodeBreak300 - #CABINET - #GASTFOX Full 📢: - https://t.co/oO0ErxWu5B - https://t.co/bqb1o0FiD7 - Also on the “Oncology Brothers” podcast #MedTwitter #OncTwitter @myESMO #gism #crcsm @TargetedOnc

Oncoinfo @Oncoinfo_it

over 2 years ago

#ESMO23 | @FilippoPietran4 reports on key results on the #CodeBreak300 phase 3 study: sotorasib + panitumumab vs standard-of-care for chemorefractory KRAS G12C-mutated #mCRC

Oncoinfo @Oncoinfo_it

almost 3 years ago

#ESMO23 | @ChiaraCrem1: “The combination of sotorasib and panitumumab will likely become a new standard of care for KRAS G12C mutant #mCRC patients”. #CodeBreak300 @FilippoPietran4 @myESMO @GillSharlene @CarmeloPozzo @IstTumori @Unipisa

Lisa Salvatore @LisaSalvy

almost 3 years ago

@FilippoPietran4 excellent talk!!! Soto+Pani improves PFS and RR vs standard therapy in chemorefractory KRAS G12C mCRC patients. Fil you are the number one #ESMO23 #codebreak300 #nejm

$LisaSalvy's tweet photo. @FilippoPietran4 excellent talk!!! Soto+Pani improves PFS and RR vs standard therapy in chemorefractory KRAS G12C mCRC patients. Fil you are the number one #ESMO23 #codebreak300 #nejm https://t.co/zlQrgAieDt$

365

Oriol Mirallas MD

@DrMirallas

almost 3 years ago

#ESMO23 📢Presidential2 @myESMO #CODEBREAK300 Sotorasib 960mg/240mg + Panitumumab vs IC TAS/Rego for #KRASG12C #CCR 🗣️ @FilippoPietran4 📌 mPFS 5.6m/3.6m HR 0.49/0.58 📌 ORR 26/6% mDor 5.8 ☣️ >G3 35/30% @ASCO @OncoAlert @OncBrothers @_SEOM Discussed by Dr. Koopman

DrMirallas's tweet photo. #ESMO23
📢Presidential2 @myESMO
#CODEBREAK300 Sotorasib 960mg/240mg + Panitumumab vs IC TAS/Rego for #KRASG12C #CCR
🗣️ @FilippoPietran4
📌 mPFS 5.6m/3.6m HR 0.49/0.58
📌 ORR 26/6% mDor 5.8
☣️ >G3 35/30%
@ASCO @OncoAlert @OncBrothers @_SEOM
Discussed by Dr. Koopman https://t.co/Z0TKLrddk4

Dario Trapani @darioT_

almost 3 years ago

@FilippoPietran presenting the #CodeBreak300 with EGFR/KRAS double 🎯🎯 & dose-optimization clinical trial in advanced #CRC at #ESMO23 👇🏻👇🏻👇🏻

darioT_'s tweet photo. @FilippoPietran presenting the #CodeBreak300 with EGFR/KRAS double 🎯🎯 & dose-optimization clinical trial in advanced #CRC at #ESMO23

👇🏻👇🏻👇🏻 https://t.co/DN79gEL72y

Jeroen Dekervel @JDekervel

almost 3 years ago

#ESMO2023 Late Breaking Abstracts #CodeBreaK300 - Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated metastatic colorectal cancer ⬆️ PFS ⬆️ efficacy signal in higher dose sotorasib (960 mg) ⏱️ OS pending

$JDekervel's tweet photo. #ESMO2023 Late Breaking Abstracts #CodeBreaK300 - Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated metastatic colorectal cancer ⬆️ PFS ⬆️ efficacy signal in higher dose sotorasib (960 mg) ⏱️ OS pending https://t.co/VG2G2JsiDS$

Oncology Brothers

@OncBrothers

almost 3 years ago

< 3 weeks to #ESMO23, here is a📝 of 🔑abstracts for general onc that could change our SoC! - #ALINA - #LIBRETTO431 - #TROPIONLung01 - #MARIPOSA - #Ev302 - #CM901 - #LITESPARK005 - #KN756 - #CABINET - #CODEBREAK300 #BCSM #GISM #LCSM #MedTwitter #GUSM #OncTwitter @myESMO

OncBrothers's tweet photo. < 3 weeks to #ESMO23, here is a📝 of 🔑abstracts for general onc that could change our SoC!

- #ALINA
- #LIBRETTO431
- #TROPIONLung01
- #MARIPOSA
- #Ev302
- #CM901
- #LITESPARK005
- #KN756
- #CABINET
- #CODEBREAK300

#BCSM #GISM #LCSM #MedTwitter #GUSM #OncTwitter @myESMO https://t.co/yxmLGNbDrZ

333

121

81K

Top Tweets for #CodeBreak300

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users